| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 1 security · may seek to influence control | ||||||
|
Qualigen Therapeutics, Inc.
13D/A
QLGN · 74754R103
|
20.0% |
11/19/2025
Event 11/17/2025
|
||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.